Table 3.

Off-label drugs against SARS-CoV-2 and COVID-19 disease [92].

Drug	Class	Target	Dosage	References
Camostat mesilate	Serine protease inhibitor	TMPRSS2	200 mg three times daily, for 2 weeks, per oral	[73,74]
Nafamostat mesilate	Serine protease inhibitor	TMPRSS2	240 mg daily, for 5 days, per oral	[75]
Chloroquine phosphate	Antimalarial drug	ACE2	250 mg daily until clinical convalescence, per oral	[78,79]
Hydroxychloroquine	Antimalarial drug	Endosome, pH elevation	400 mg loading dose twice daily at day 1, 200 mg twice daily for 4 days, or 600 mg for 6 days, or 400 mg for 5 days, per oral	[[80], [81], [82]]
Remdesivir	Antiviral drug	RdRp	200 mg loading dose at day 1, 100 mg for 9–13 days, per oral or intravenous	[[83], [84], [85]]
Lopinavir/ritonavir	Antiviral drug	Viral proteases	400 mg lopinavir and 100 mg ritonavir twice daily, for 14 days, per oral	[[86], [87], [88]]
Umifenovir	Antiviral drug	Membrane fusion, clathrin-mediated endocytosis	400 mg three times daily, for 9 days, per oral	[89,90]
Favipiravir	Antiviral drug	RdRp	6000 mg loading dose at day 1, 2, 400 mg for days 2–10, per oral	[91]